Pfizer’s Q2 Focus: Core Products And New Ventures
Summary: Analysts predict Pfizer’s Q2 2024 revenue to be around $13 billion. The EPS estimate
Summary: Analysts predict Pfizer’s Q2 2024 revenue to be around $13 billion. The EPS estimate
Summary: Pfizer Inc. announced today that it planned to continue development of its GLP-1 agonist
Summary: Paxlovid treatment consists, each dose, of three pills: two of nirmatrelvir and one of
Summary: Pfizer’s recent financial performance and Wall Street analysts’ expectations around the upcoming quarterly earnings
Summary: When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is
Summary: Pfizer CEO announced testing of three new weight loss drugs, one with a different
Summary: Since the publication of my last article, Pfizer has continued to surprise me pleasantly.
Summary: Pfizer’s stock initially showed signs of recovery, but then stagnated while the rest of
Summary: A difficult period for Pfizer might be coming to an end, as serious setbacks
Summary: Pfizer is expected to experience growth in cancer treatments due to the rising global